Charcot-Marie-Tooth type 1A (CMT1A) neuropathies linked to the misexpression of peripheral myelin protein 22 (PMP22) are progressive demyelinating disorders of the peripheral nervous system. In this study we asked whether dietary restriction by intermittent fasting (IF) could alleviate the neuropathic phenotype in the Trembler J (TrJ) mouse model of CMT1A. Our results show that neuropathic mice kept on a five month long IF regimen had improved locomotor performance compared to ad libitum (AL) fed littermates. The functional benefits of this dietary intervention are associated with an increased expression of myelin proteins combined with a thicker myelin sheath, less redundant basal lamina, and a reduction in aberrant Schwann cell proliferation. These morphological improvements are accompanied by a decrease in PMP22 protein aggregates, and enhanced expression of cytosolic chaperones and constituents of the autophagy-lysosomal pathway. These results indicate that dietary restriction is beneficial for peripheral nerve function in TrJ neuropathic mice, as it promotes the maintenance of locomotor performance.
Introduction
Alterations in peripheral myelin protein 22 (PMP22) gene expression are linked to heritable demyelinating peripheral neuropathies, a heterogeneous group of diseases that lead to progressive myelin instability and slowed nerve conduction velocity (Suter and Snipes, 1995) . Affected individuals present with sensory and motor disturbances, muscle weakness and atrophy. In humans, the autosomal dominantly inherited Charcot-Marie-Tooth (CMT) disease is most frequently associated with duplication of a 1.5 Mb region on chromosome 17, including the intact PMP22 gene (CMT1A). In a smaller group of CMT1A, and in the severe Dejerine-Sottas Syndrome (DSS) patients, single amino acid substitutions in PMP22 are present (Sanders et al., 2001) . The spontaneous mutant Trembler J (TrJ) mouse carries the identical L16P amino acid substitution in the peripheral myelin protein 22 gene as has been identified in patients with CMT1A (Suter et al., 1992; Valentijn et al., 1992) and models the behavioral and histopathological phenotypes of the disease (Notterpek and Tolwani, 1999) .
The pathological findings in neuropathic mouse nerves include degenerating axonal profiles, incomplete myelination, excessive proliferation of Schwann cells and redundant basal lamina (Henry et al., 1983) . How the abnormal expression of PMP22 leads to such a complex phenotype remains unclear, but altered processing and turnover rate of the mutated protein within Schwann cells are likely to play roles. Studies in Schwann cells indicate that ∼80% of the newlysynthesized wild type (Wt) protein is rapidly degraded by the proteasome, presumably due to misfolding (Pareek et al., 1997; Notterpek et al., 1999) . In the disease states, when one copy of PMP22 is mutated, the fraction destined for proteasomal degradation is increased, which overwhelms the proteasome and leads to protein aggregate formation (Fortun et al., 2003) . Data from multiple laboratories support the involvement of protein mistrafficking and aggregation in PMP22 neuropathies (Isaacs et al., 2002; Ryan et al., 2002; Tobler et al., 2002; Fortun et al., 2003 Fortun et al., , 2006 , a finding that is supported by studies of nerve biopsies from patients with PMP22 gene duplication, and point mutations (Nishimura et al., 1996; Hanemann et al., 2000) . Cytosolic mislocalization of PMP22 alters protein homeostasis within Schwann cells and leads to the accumulation of ubiquitin, myelin proteins, chaperones and components of the proteasome near and within the aggregates (Ryan et al., 2002; Fortun et al., 2003 Fortun et al., , 2006 
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